ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OVID vs EOLS // EV/EBITDA & P/E VALUATION

Ovid Therapeutics Inc. (NASDAQ) VS. Evolus Inc. (NASDAQ) • 15-METRIC TALLY: OVID 6 — EOLS 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OVID VS. EOLS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OVID EOLS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 66.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -28.50% -35.00% +6.50 OVID /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -7.67% -9.20% +1.53 OVID /fcf-yield <GO>
Operating Margin -60.00% -11.00% -49.00 EOLS /operating-margins <GO>
Net Profit Margin -60.00% -17.40% -42.60 EOLS /net-margins <GO>
Revenue Growth (YoY) 180.00% 11.60% +168.40 OVID /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 11.46 0.20 +11.26 OVID /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 EOLS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.1 46.1 +9.98 OVID /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $500.0M $496.7M $3.3M OVID /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OVID REV EOLS REV OVID GROSS % EOLS GROSS % OVID FCF EOLS FCF
FY 2025 $7.3M $297.2M — 66.3% -$38.3M -$45.7M
FY 2024 $566.0K $266.3M — 68.5% -$56.0M -$19.5M
FY 2023 $392.0K $202.1M — — -$45.8M -$34.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OVID // BETA —
EOLS // BETA —